Trial Profile
Multi-centre real-world study of boceprevir-based triple therapy in genotype 1 hepatitis C: the Australian multi-centre Boceprevir real world experience (SABRE-C)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Aug 2015
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Interferon; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms SABRE-C
- 28 Aug 2015 New trial record